PMOS and trying to conceive

If you have a PCOS diagnosis, what you have is now formally called PMOS (polyendocrine metabolic ovarian syndrome), the new name confirmed by global consensus in May 2026. The diagnostic criteria did not change. The clinical condition did not change. The fertility considerations did not change. The 2023 International Guideline remains the anchor for what current evidence supports in PMOS fertility care.

The data on PMOS and conception are more reassuring than the conversation around them suggests. Long-running registry studies in the Nordic countries show that women with PMOS are about as likely as their peers to have at least one child. The path often takes longer, often involves a medication or two, and almost always benefits from a workup that the standard family-doctor visit does not include. The endpoint, for most people who want to reach it, is reachable.

This article walks through what the path actually looks like under the 2023 Guideline: confirming ovulation, when to ask for a workup, what letrozole is and why it replaced clomiphene as first-line, where metformin and inositol fit, when to escalate, and what to plan for if you conceive. It is general information about a clinical area; the decisions belong with a reproductive-medicine team.

What the long-run picture actually shows

The dominant fertility issue in PMOS is ovulatory dysfunction. The ovaries develop multiple follicles each cycle, but few or none mature far enough to release an egg reliably. Insulin resistance, an elevated luteinising hormone (LH) relative to follicle-stimulating hormone (FSH) ratio, and elevated androgens together disrupt the orderly follicular selection that normally produces one dominant follicle per cycle.

That is the proximate problem. It is also a problem with multiple effective interventions, which is why the long-term outcomes look so different from the short-term experience.

Studies tracking women with PMOS over 20 to 30 years find cumulative pregnancy rates approaching the general population, in roughly the 70 to 80 percent range when fertility treatment is available. The challenge is mostly time-to-pregnancy and access to the right care, not the binary outcome. Two cautions are worth holding alongside that picture:

Time matters.PMOS does not accelerate ovarian aging; if anything, anti-Müllerian hormone (AMH) levels stay higher for longer than in age-matched peers. But the longer a cycle-by-cycle process takes, and the higher the chance of needing assisted reproduction, the earlier a workup is worth starting.

Some couples have additional factors. Tubal disease, male-factor infertility, and unexplained infertility do not disappear because PMOS is the headline diagnosis. A complete workup looks at all of these.

Are you actually ovulating?

This is the question that determines what comes next. A regular cycle is not the same as ovulation. Anywhere from 20 to 40 percent of women with PMOS who report regular cycles are still anovulating intermittently.

The cleanest way to confirm ovulation in a given cycle is a mid-luteal progesterone level. A blood draw seven days before the expected next period (roughly cycle day 21 in a 28-day cycle) is the standard. A progesterone level above approximately 3 ng/mL confirms ovulation happened in that cycle; above 10 ng/mL is more reassuring of a robust corpus luteum.

Cheaper and less precise alternatives:

• Ovulation predictor kits (OPKs) detect the LH surge. They work for many people with PMOS, but the chronically elevated baseline LH common in PMOS makes false positives more likely. A persistent positive without an actual ovulation is not unusual.
• Basal body temperature (BBT) charting shows a sustained rise after ovulation. Useful retrospectively, less useful for timing intercourse to a specific window.
• Continuous-temperature wearables (Oura ring, Apple Watch wrist-temperature, etc.) have made BBT-style detection more practical. They are not medical-grade, but the trend across weeks can be informative.

For the bigger picture on cycle interpretation when cycles are irregular, see the cycle irregularity mechanism page.

When to ask for a workup

The international rule of thumb, the same one that applies in non-PMOS infertility, is:

• 12 months of trying without success, if the partner with ovaries is under 35.
• 6 months, if 35 or older.

For PMOS specifically, two adjustments are worth knowing.

First, if cycles are clearly irregular or anovulatory, the "trying" window is partly a fiction. A 12-month wait for a non-ovulating cycle to produce a pregnancy is not going to change the answer. Many fertility specialists will start a workup earlier in this case, or at the first appointment, rather than wait through the standard window.

Second, age weights heavily. Someone 38 with irregular PMOS cycles has more reason to start the conversation now than someone 26 with the same picture. Time-to-decision compounds with age in a way that time-to-pregnancy does not.

A reasonable initial workup includes confirmation of ovulation status, an AMH for ovarian reserve baseline, a semen analysis for the partner if applicable, a hysterosalpingogram (HSG) or saline sonogram to confirm tubal patency, and the standard PMOS labs if those have not already been done. The care-prep guide on PMOS diagnosis covers the lab side.

Letrozole is the 2023 first-line

This is the single most important practical update in PMOS fertility care over the past decade, and it still has not fully reached every clinic. The 2023 International Guideline names letrozole as the preferred first-line pharmacological treatment for ovulatory dysfunction in PMOS, replacing clomiphene citrate, which had held that position since the 1960s.

The change rests on the 2014 PPCOS II trial, a 750-woman, multicentre, double-blind randomised controlled trial published in the New England Journal of Medicine, alongside a sequence of meta-analyses since then. Letrozole produced higher live-birth rates than clomiphene (approximately 27.5 percent versus 19.1 percent across the trial’s five cycles), with no increase in birth defects. A 2023 umbrella review confirmed thicker endometrium, higher ovulation rates, and higher pregnancy rates with letrozole across more than 75,000 women in 50 RCTs.

Why letrozole works better in PMOS specifically. Clomiphene blocks oestrogen receptors throughout the body, including in the endometrium, which thins the lining and degrades cervical mucus. Letrozole, an aromatase inhibitor used in breast oncology in different contexts, lowers oestrogen production briefly during the dosing window and allows the endometrial lining to recover during the rest of the cycle. The pregnancy environment is friendlier as a result.

What it looks like in practice:

• Standard starting dose: 2.5 mg daily for 5 days, usually cycle days 3 through 7 (sometimes 2 through 6).
• If no ovulatory response, escalate to 5 mg, then 7.5 mg in subsequent cycles.
• Monitoring: typically a follicle scan around cycle day 11 to 14, plus confirmation of ovulation.
• Most pregnancies in responders occur within the first 3 to 4 cycles.

Side effects are usually mild (hot flushes, fatigue, occasional headaches) and shorter-lived than clomiphene’s, because letrozole’s half-life is approximately two days compared with clomiphene’s extended persistence.

Where metformin and inositol fit

Both come up constantly in the fertility conversation. Both have a real but specific role.

Metformin. For ovulation induction, meta-analyses consistently show that metformin alone is less effective than letrozole alone for live birth. Adding metformin to clomiphene improves outcomes over clomiphene alone, which is useful in clomiphene-resistant cases. Adding metformin to letrozole does not appear to outperform letrozole alone for the primary endpoints.

Where metformin earns its place in PMOS fertility:

• Reducing the risk of ovarian hyperstimulation syndrome (OHSS) in IVF cycles using long agonist protocols.
• Possibly reducing first-trimester miscarriage rates. A 2025 meta-analysis suggested benefit when metformin is continued through the first trimester, and the field is actively debating whether the international guidelines should be updated to reflect this.
• Managing the metabolic burden when insulin resistance is significant, alongside the fertility-specific work.

Inositol. Inositol can help restore some spontaneous ovulation in PMOS, particularly in the metabolically-driven phenotype. The evidence is rated "limited and inconclusive" by the 2023 Guideline’s own meta-analysis. Inositol is a reasonable adjunct, particularly before starting letrozole, or as a low-friction first step. It is not a substitute for ovulation induction in someone who is actively trying to conceive on a defined timeline. The evidence summary on inositol covers the fuller picture.

When letrozole is not enough

Approximately 20 to 25 percent of women will not ovulate or conceive with letrozole monotherapy across multiple cycles. The next steps escalate predictably under the 2023 Guideline:

Second-line: gonadotropins or laparoscopic ovarian surgery. Low-dose gonadotropins (recombinant FSH) injections can drive ovulation when oral agents have not produced a response. They require ultrasound monitoring to manage OHSS and multiple-pregnancy risk. Laparoscopic ovarian drilling is also second-line per the 2023 Guideline, although in countries with good access to ovulation induction medications and IVF it is used less frequently.

Third-line: in vitro fertilisation (IVF). For couples who do not conceive with second-line approaches, or who have additional factors (tubal disease, severe male factor), IVF is the next step. PMOS-specific considerations: women with PMOS are at higher risk for OHSS during stimulation, which is why GnRH antagonist protocols with agonist triggers are commonly preferred. In vitro maturation (IVM), where eggs are matured in the lab rather than the ovary, can further reduce OHSS risk and is used selectively in some centres.

Escalation to second- or third-line is not failure. The interventions work at different points; some PMOS phenotypes respond to letrozole, some respond to gonadotropins, some need IVF. The pathway is well-established. The right next step depends on which point of the path the cycle data has reached.

Once you conceive: what changes

PMOS pregnancies carry elevated risk for several specific things, and knowing them lets the obstetric team screen earlier rather than later:

• Gestational diabetes. Risk is approximately doubled. Screening at 24 to 28 weeks of gestation is standard, but PMOS pregnancies often warrant a first-trimester baseline as well.
• Hypertensive disorders of pregnancy. Gestational hypertension and preeclampsia rates are elevated, especially when pre-pregnancy insulin resistance is significant.
• Preterm birth. Risk is modestly elevated, particularly in PMOS plus elevated BMI.
• Miscarriage. Historic data suggest first-trimester rates approximately 30 to 50 percent higher than non-PMOS rates. The 2025 first-trimester metformin meta-analysis suggests metformin may reduce this for some women, though this is still being integrated into the international guidelines.

None of this means a PMOS pregnancy is fragile by default. Most progress completely uneventfully. It does mean that flagging PMOS at the first prenatal visit, asking specifically about early gestational diabetes screening, and continuing close metabolic monitoring through pregnancy are worth the extra time at the booking appointment.

What this means for the next visit

If you are at the start of trying, the concrete asks:

• A confirmation of ovulation status: mid-luteal progesterone, or a wearable trend across a few cycles.
• The PMOS workup if it has not been done properly. The care-prep guide on diagnosis covers what a complete workup includes.
• An AMH for ovarian reserve baseline.
• A semen analysis for the partner if applicable, before assuming PMOS is the only factor.

If you have been trying for the threshold time without success, the concrete ask is a referral to a reproductive endocrinologist and a conversation about starting letrozole. If a clinician is defaulting to clomiphene, asking why is reasonable. There are sometimes specific reasons (cost, access, individual preference, contraindication), but they should be specific to your case, not default practice.

A note on the conversation

The fertility journey in PMOS is one of the cases where the long-run data is genuinely more encouraging than the short-run experience suggests. The interventions work. The hierarchy is well-established. The system is sometimes slower than it should be.

That is true, and it is true alongside the real difficulty of a long path. Time-to-pregnancy can be measured in months and sometimes in years. Each cycle that does not produce a pregnancy is its own moment. The data about cumulative outcomes does not replace what those months feel like to live through.

What current evidence supports is that, for most people with PMOS who want to conceive and have access to the right care, the destination is reachable. The interventions described in this article are the ones that have moved the most weight in that direction. The next visit is the next step on the path; that is most of what this article is meant to support.